Adicet Bio, Inc. Files 8-K for Material Agreement
Ticker: ACET · Form: 8-K · Filed: Mar 22, 2024 · CIK: 1720580
| Field | Detail |
|---|---|
| Company | Adicet Bio, Inc. (ACET) |
| Form Type | 8-K |
| Filed Date | Mar 22, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, filing
TL;DR
Adicet Bio just signed a big deal, filing an 8-K today.
AI Summary
On March 22, 2024, Adicet Bio, Inc. entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits. The company's principal executive offices are located at 131 Dartmouth Street, Floor 3, Boston, Massachusetts.
Why It Matters
This 8-K filing indicates a significant new agreement for Adicet Bio, Inc., which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material Definitive Agreements can introduce new risks or opportunities that are not yet fully understood.
Key Numbers
- 001-38359 — Commission File Number (Identifies the company's SEC filing history)
- 81-3305277 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Adicet Bio, Inc. (company) — Registrant
- March 22, 2024 (date) — Date of earliest event reported
- 131 Dartmouth Street, Floor 3, Boston, Massachusetts 02116 (location) — Address of Principal Executive Offices
- resTORbio, Inc. (company) — Former company name
FAQ
What is the nature of the Material Definitive Agreement Adicet Bio, Inc. entered into?
The filing states that Adicet Bio, Inc. entered into a Material Definitive Agreement on March 22, 2024, but the specific details of the agreement are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 22, 2024.
What is Adicet Bio, Inc.'s principal executive office address?
Adicet Bio, Inc.'s principal executive office is located at 131 Dartmouth Street, Floor 3, Boston, Massachusetts 02116.
What was Adicet Bio, Inc.'s former company name?
Adicet Bio, Inc.'s former company name was resTORbio, Inc.
What is the Commission File Number for Adicet Bio, Inc.?
The Commission File Number for Adicet Bio, Inc. is 001-38359.
Filing Stats: 928 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2024-03-22 16:15:44
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ACET The Nasdaq Global Ma
Filing Documents
- acet-20240322.htm (8-K) — 47KB
- acet-ex1_1.htm (EX-1.1) — 340KB
- acet-ex5_1.htm (EX-5.1) — 15KB
- 0000950170-24-035366.txt ( ) — 578KB
- acet-20240322.xsd (EX-101.SCH) — 24KB
- acet-20240322_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On March 22, 2024, Adicet Bio, Inc. (the "Company") entered into an Open Market Sales Agreement SM (the "Sales Agreement") with Jefferies LLC ("Jefferies") to sell shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), from time to time, through an "at the market" equity offering program under which Jefferies will act as sales agent or principal. Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, Jefferies may sell the shares (a) in privately negotiated transactions with the consent of the Company; (b) as block transactions; or (c) by any other method permitted by law deemed to be an "at the market" offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, including sales made through The Nasdaq Global Market or any other trading market for our common stock. In addition, Jefferies may also sell shares to Jefferies acting as principal for Jefferies' own account. Jefferies will use its commercially reasonable efforts in conducting sales activities consistent with its normal trading and sales practices. Jefferies and the Company each have the right, by giving written notice as specified in the Sales Agreement, to terminate the Sales Agreement in each party's sole discretion at any time. The Sales Agreement provides that Jefferies will be entitled to compensation for its services an amount equal to 3.0% of the gross proceeds of any shares of common stock sold through Jefferies under the Sales Agreement. Jefferies and the Company have no obligation to sell any shares under the Sales Agreement and may at any time suspend any sale under the Sales Agreement. The shares will be issued pursua
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Open Market Sales Agreement SM , dated as of March 22, 2024, by and between the Company and Jefferies LLC 5.1 Opinion of Goodwin Procter LLP 23.1 Consent of Goodwin Procter LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADICET BIO, INC. Date: March 22, 2024 By: /s/ Nick Harvey Name: Nick Harvey Title: Chief Financial Officer